Novartis (NVS) Stock Surges 5% Following Positive Multiple Sclerosis Drug Trial Results

Key Takeaways

Table of Contents

Shares of Novartis climbed approximately 5% following positive Phase 3 trial outcomes for remibrutinib, an oral multiple sclerosis treatment
The experimental drug outperformed teriflunomide (marketed as Aubagio by Sanofi) in decreasing relapse frequency among relapsing MS patients
Remibrutinib demonstrated significant benefits in reducing disability progression without raising hepatic safety flags
The pharmaceutical giant suspended eight clinical studies of rap-cel, an investigational cell-based therapy, following three patient fatalities from severe immune complications
Oncology-focused trials remained unaffected by the rap-cel suspension; Novartis intends to pursue worldwide regulatory clearance for remibrutinib

Shares of Novartis experienced a substantial uptick of nearly 5% during early Tuesday market activity following the pharmaceutical company’s announcement of positive data from two Phase 3 clinical studies evaluating remibrutinib, an investigational oral therapy for multiple sclerosis.

Novartis AG, NVS

The clinical programs, designated REMODEL-1 and REMODEL-2, evaluated remibrutinib’s performance against teriflunomide, a currently marketed oral MS medication distributed by Sanofi as Aubagio. Results showed remibrutinib achieved superiority on primary endpoints in both investigations.

The experimental therapy exhibited superior efficacy compared to teriflunomide in minimizing relapse frequency among adult participants diagnosed with relapsing multiple sclerosis (RMS). Additionally, the compound delivered clinically significant benefits in decelerating disability advancement.

According to Novartis, remibrutinib displayed favorable tolerability profiles throughout both clinical studies. Notably, investigators identified no hepatic safety signals, aligning with observations from previous early-phase research.

Shreeram Aradhye, Novartis’s president of development and chief medical officer, highlighted the persistent unmet medical need in this therapeutic area. He emphasized the importance of developing oral medications capable of providing robust relapse control and delayed disability worsening while maintaining acceptable safety standards.

“The positive REMODEL results underscore the potential of remibrutinib as a high-efficacy oral therapy for people living with RMS with a differentiated benefit-risk profile,” Aradhye said.

The company announced intentions to submit remibrutinib for regulatory review across global markets. Complete trial findings are scheduled for presentation at a forthcoming medical conference in Toronto.

Safety Concerns Halt Separate CAR-T Program

Concurrent with the multiple sclerosis announcement, Novartis disclosed that it had suspended eight clinical investigations of rap-cel, a distinct experimental treatment, in late August following three patient deaths attributed to severe, potentially fatal immune system reactions.

The suspension took effect on August 24. According to Novartis, the fatalities resulted from a condition where the immune system becomes hyperactivated and targets the body’s own tissues and organs—a recognized complication associated with CAR-T therapeutic approaches.

Rap-cel represents a CAR-T therapeutic platform that engineers a patient’s own immune cells to identify and eliminate specific cellular targets. The suspended studies encompassed autoimmune conditions including systemic lupus erythematosus, rheumatoid arthritis, and vasculitis, alongside neurological disorders such as multiple sclerosis and myasthenia gravis.

Novartis stated it is undertaking a comprehensive investigation of these adverse events and collaborating with independent safety monitoring committees to determine contributing factors and develop improved early detection protocols for serious adverse reactions.

Oncology Studies Continue Uninterrupted

The pharmaceutical company clarified that its two active clinical trials enrolling lymphoma and leukemia patients remained operational and were not impacted by the rap-cel program suspension. Novartis indicated it is providing updates to regulatory agencies and maintaining close surveillance of individuals who previously received the investigational therapy.

The Wall Street Journal initially disclosed the trial suspension. The publication additionally reported that Bristol Myers Squibb had implemented precautionary holds on comparable CAR-T studies in autoimmune disease populations. Bristol Myers Squibb declined to provide commentary when contacted.

Notwithstanding the rap-cel developments, market participants concentrated on the encouraging remibrutinib outcomes. Novartis shares were trading approximately 4% higher on Tuesday.

✨ Limited Time Offer